HCPCS Level II code V2790 identifies the use of amniotic membrane for surgical reconstruction, billed per procedure. The code captures a biologic graft product employed across surgical specialties to support wound healing, ocular and soft-tissue reconstruction, and other reparative surgical applications. Its national relevance stems from growing use of biologic and tissue-based products in reconstructive surgery and the need for clear billing pathways.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, coding and billing considerations, and clinical contexts where V2790 is commonly applied. The publication summarizes benchmarks for utilization where available, highlights policy updates affecting coverage and documentation expectations, and provides clinical context for typical sites of service and procedure types that use this product.

This summary is intended for coding professionals, revenue cycle staff, and clinicians seeking a concise reference on the code's purpose, payer landscape, and the kinds of metrics and policy information typically relevant when billing for amniotic membrane used in surgical reconstruction.